Literature DB >> 20520597

Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362.

Steven Boakes1, Antony N Appleyard, Jesús Cortés, Michael J Dawson.   

Abstract

Deoxyactagardine B (DAB) is a hitherto unknown type B lantibiotic, produced by Actinoplanes liguriae NCIMB41362. The mature peptide is 19 amino acids in length and structurally analogous to actagardine, differing by two amino acids (V15L and I16V) and the absence of a sulfoxide bond between residues 14 and 19. The biosynthetic genes encoding DAB are clustered, and in addition to the structural gene ligA include genes believed to encode for the proteins responsible for the modification, transport and regulation of DAB synthesis. Surprisingly, despite the presence of a gene that shares significant homology to the monooxygenase garO from the actagardine biosynthetic gene cluster, the oxidized form of DAB has not been detected. A lanA gene encoding the DAB peptide has been introduced into the plasmid pAGvarX and delivered into a strain of Actinoplanes garbadinensis lacking the structural gene for actagardine, garA (A. garbadinensis DeltagarA). Expression of this gene in A. garbadinensis DeltagarA resulted in the production of actagardine B, an oxidized form of DAB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20520597     DOI: 10.1038/ja.2010.48

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  10 in total

1.  Further characterization of Bacillus subtilis antibiotic biosensors and their use for antibacterial mode-of-action studies.

Authors:  Katherine R Mariner; Nicola Ooi; Deborah Roebuck; Alex J O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens.

Authors:  Daniela Jabés; Cristina Brunati; GianPaolo Candiani; Simona Riva; Gabriella Romanó; Stefano Donadio
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

3.  Heterologous production of the lantibiotic Ala(0)actagardine in Escherichia coli.

Authors:  Yanxiang Shi; Alejandro Bueno; Wilfred A van der Donk
Journal:  Chem Commun (Camb)       Date:  2012-11-18       Impact factor: 6.222

4.  Cloning and analysis of the planosporicin lantibiotic biosynthetic gene cluster of Planomonospora alba.

Authors:  Emma J Sherwood; Andrew R Hesketh; Mervyn J Bibb
Journal:  J Bacteriol       Date:  2013-03-08       Impact factor: 3.490

5.  The antibiotic planosporicin coordinates its own production in the actinomycete Planomonospora alba.

Authors:  Emma J Sherwood; Mervyn J Bibb
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

6.  Antibacterial activity of the novel semisynthetic lantibiotic NVB333 in vitro and in experimental infection models.

Authors:  Steven Boakes; William J Weiss; Mary Vinson; Sjoerd Wadman; Michael J Dawson
Journal:  J Antibiot (Tokyo)       Date:  2016-05-18       Impact factor: 2.649

7.  Towards Biocontained Cell Factories: An Evolutionarily Adapted Escherichia coli Strain Produces a New-to-nature Bioactive Lantibiotic Containing Thienopyrrole-Alanine.

Authors:  Anja Kuthning; Patrick Durkin; Stefan Oehm; Michael G Hoesl; Nediljko Budisa; Roderich D Süssmuth
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

8.  Heterologous Biosynthesis, Modifications and Structural Characterization of Ruminococcin-A, a Lanthipeptide From the Gut Bacterium Ruminococcus gnavus E1, in Escherichia coli.

Authors:  Elvis L Ongey; Robert T Giessmann; Michel Fons; Juri Rappsilber; Lorenz Adrian; Peter Neubauer
Journal:  Front Microbiol       Date:  2018-07-26       Impact factor: 5.640

Review 9.  Bacteriocins: Potential for Human Health.

Authors:  Fuqing Huang; Kunling Teng; Yayong Liu; Yanhong Cao; Tianwei Wang; Cui Ma; Jie Zhang; Jin Zhong
Journal:  Oxid Med Cell Longev       Date:  2021-04-10       Impact factor: 6.543

Review 10.  Bioengineering Lantibiotics for Therapeutic Success.

Authors:  Des Field; Paul D Cotter; Colin Hill; R P Ross
Journal:  Front Microbiol       Date:  2015-11-27       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.